Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression (Q58386415)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

title

Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Anish Thomas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Raffit Hassan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Elad Sharon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

James C Reynolds

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Alexander Ling

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Robert J Kreitman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Markku M Miettinen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Seth M Steinberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Daniel H Fowler

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

Ira Pastan

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

Science Translational Medicine

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

issue

208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

208ra147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

Advances in malignant mesothelioma

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Inflammation-based prognostic indices in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCITRANSLMED.3006941

Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1

21 January 2018

1 reference

12 December 2020

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

12 December 2020

Pentostatin: future directions

1 reference

12 December 2020

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

12 December 2020

Malignant pleural mesothelioma

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.

1 reference

12 December 2020

Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma

1 reference

12 December 2020

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

12 December 2020

10.1126/SCITRANSLMED.3006941

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24154601 AND SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

24154601

1 reference